PULIKE(603566)2025-01-17 09:05Financial Performance Expectations - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 80 million and 100 million yuan, representing a decrease of 74.5174 million to 94.5174 million yuan compared to the previous year, a decline of 42.70% to 54.16%[3]. - The expected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between 67 million and 87 million yuan, a decrease of 66.9665 million to 86.9665 million yuan year-on-year, reflecting a decline of 43.49% to 56.48%[6]. - The earnings per share for the upcoming year is estimated to be 0.50 yuan[7]. - The previous year's net profit attributable to shareholders was 174.5174 million yuan, and the net profit after deducting non-recurring gains and losses was 153.9665 million yuan[5]. Reasons for Profit Decrease - The main reasons for the profit decrease include slow recovery in demand for veterinary vaccines and chemicals, intensified market competition leading to price reductions, and significant depreciation expenses from new production facilities[8]. Strategic Response - The company plans to adjust its marketing strategy, implement organizational changes, strengthen cost control, and enhance core competitiveness to respond to industry changes and promote high-quality development[8].